Hypomethylating agent 5-Aza-2′-deoxycytidine (DAC) ameliorates multiple sclerosis in mouse models

Katia Mangano, Paolo Fagone, Klaus Bendtzen, Pier Luigi Meroni, Cinzia Quattrocchi, Santa Mammana, Michelino Di Rosa, Lucia Malaguarnera, Marinella Coco, Gaetano Magro, Roberto Di Marco, Ferdinando Nicoletti

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Increasing evidence supports the role of epigenetics in the development of autoimmune disorders and the possibility of using epigenetic modifying drugs in the context of MS has not yet been investigated. We have explored the effect of the hypomethylating agent 5-aza-2′-deoxycytidine (DAC) in two murine models of experimental allergic encephalomyelitis (EAE). DAC treatment was associated with a significant amelioration of the clinical and histological hallmarks of EAE in both models. These effects were observed both in prophylactic and therapeutic regimens. The milder course of the disease was associated with a reduction in the number of spinal cord infiltrating lymphocytes and amelioration of the histopathological signs associated with EAE. In addition, increased transcript levels of anti-inflammatory cytokines and decreased mRNA expression of pro-inflammatory mediators were also observed. Finally, DAC treatment increased the percentage of circulating regulatory T cells by inducing Foxp3 expression via demethylation of a CpG island in Foxp3.

Original languageEnglish
Pages (from-to)1918-1925
Number of pages8
JournalJournal of Cellular Physiology
Volume229
Issue number12
DOIs
Publication statusPublished - 2014

Fingerprint

decitabine
Autoimmune Experimental Encephalomyelitis
Multiple Sclerosis
Epigenomics
CpG Islands
T-cells
Lymphocytes
Anti-Inflammatory Agents
Regulatory T-Lymphocytes
Cytokines
Messenger RNA
Spinal Cord
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Cell Biology
  • Physiology

Cite this

Mangano, K., Fagone, P., Bendtzen, K., Meroni, P. L., Quattrocchi, C., Mammana, S., ... Nicoletti, F. (2014). Hypomethylating agent 5-Aza-2′-deoxycytidine (DAC) ameliorates multiple sclerosis in mouse models. Journal of Cellular Physiology, 229(12), 1918-1925. https://doi.org/10.1002/jcp.24641

Hypomethylating agent 5-Aza-2′-deoxycytidine (DAC) ameliorates multiple sclerosis in mouse models. / Mangano, Katia; Fagone, Paolo; Bendtzen, Klaus; Meroni, Pier Luigi; Quattrocchi, Cinzia; Mammana, Santa; Di Rosa, Michelino; Malaguarnera, Lucia; Coco, Marinella; Magro, Gaetano; Di Marco, Roberto; Nicoletti, Ferdinando.

In: Journal of Cellular Physiology, Vol. 229, No. 12, 2014, p. 1918-1925.

Research output: Contribution to journalArticle

Mangano, K, Fagone, P, Bendtzen, K, Meroni, PL, Quattrocchi, C, Mammana, S, Di Rosa, M, Malaguarnera, L, Coco, M, Magro, G, Di Marco, R & Nicoletti, F 2014, 'Hypomethylating agent 5-Aza-2′-deoxycytidine (DAC) ameliorates multiple sclerosis in mouse models', Journal of Cellular Physiology, vol. 229, no. 12, pp. 1918-1925. https://doi.org/10.1002/jcp.24641
Mangano, Katia ; Fagone, Paolo ; Bendtzen, Klaus ; Meroni, Pier Luigi ; Quattrocchi, Cinzia ; Mammana, Santa ; Di Rosa, Michelino ; Malaguarnera, Lucia ; Coco, Marinella ; Magro, Gaetano ; Di Marco, Roberto ; Nicoletti, Ferdinando. / Hypomethylating agent 5-Aza-2′-deoxycytidine (DAC) ameliorates multiple sclerosis in mouse models. In: Journal of Cellular Physiology. 2014 ; Vol. 229, No. 12. pp. 1918-1925.
@article{ba94fbce22414ea388aaf317a61b571a,
title = "Hypomethylating agent 5-Aza-2′-deoxycytidine (DAC) ameliorates multiple sclerosis in mouse models",
abstract = "Increasing evidence supports the role of epigenetics in the development of autoimmune disorders and the possibility of using epigenetic modifying drugs in the context of MS has not yet been investigated. We have explored the effect of the hypomethylating agent 5-aza-2′-deoxycytidine (DAC) in two murine models of experimental allergic encephalomyelitis (EAE). DAC treatment was associated with a significant amelioration of the clinical and histological hallmarks of EAE in both models. These effects were observed both in prophylactic and therapeutic regimens. The milder course of the disease was associated with a reduction in the number of spinal cord infiltrating lymphocytes and amelioration of the histopathological signs associated with EAE. In addition, increased transcript levels of anti-inflammatory cytokines and decreased mRNA expression of pro-inflammatory mediators were also observed. Finally, DAC treatment increased the percentage of circulating regulatory T cells by inducing Foxp3 expression via demethylation of a CpG island in Foxp3.",
author = "Katia Mangano and Paolo Fagone and Klaus Bendtzen and Meroni, {Pier Luigi} and Cinzia Quattrocchi and Santa Mammana and {Di Rosa}, Michelino and Lucia Malaguarnera and Marinella Coco and Gaetano Magro and {Di Marco}, Roberto and Ferdinando Nicoletti",
year = "2014",
doi = "10.1002/jcp.24641",
language = "English",
volume = "229",
pages = "1918--1925",
journal = "Journal of cellular and comparative physiology",
issn = "0021-9541",
publisher = "Wiley-Liss Inc.",
number = "12",

}

TY - JOUR

T1 - Hypomethylating agent 5-Aza-2′-deoxycytidine (DAC) ameliorates multiple sclerosis in mouse models

AU - Mangano, Katia

AU - Fagone, Paolo

AU - Bendtzen, Klaus

AU - Meroni, Pier Luigi

AU - Quattrocchi, Cinzia

AU - Mammana, Santa

AU - Di Rosa, Michelino

AU - Malaguarnera, Lucia

AU - Coco, Marinella

AU - Magro, Gaetano

AU - Di Marco, Roberto

AU - Nicoletti, Ferdinando

PY - 2014

Y1 - 2014

N2 - Increasing evidence supports the role of epigenetics in the development of autoimmune disorders and the possibility of using epigenetic modifying drugs in the context of MS has not yet been investigated. We have explored the effect of the hypomethylating agent 5-aza-2′-deoxycytidine (DAC) in two murine models of experimental allergic encephalomyelitis (EAE). DAC treatment was associated with a significant amelioration of the clinical and histological hallmarks of EAE in both models. These effects were observed both in prophylactic and therapeutic regimens. The milder course of the disease was associated with a reduction in the number of spinal cord infiltrating lymphocytes and amelioration of the histopathological signs associated with EAE. In addition, increased transcript levels of anti-inflammatory cytokines and decreased mRNA expression of pro-inflammatory mediators were also observed. Finally, DAC treatment increased the percentage of circulating regulatory T cells by inducing Foxp3 expression via demethylation of a CpG island in Foxp3.

AB - Increasing evidence supports the role of epigenetics in the development of autoimmune disorders and the possibility of using epigenetic modifying drugs in the context of MS has not yet been investigated. We have explored the effect of the hypomethylating agent 5-aza-2′-deoxycytidine (DAC) in two murine models of experimental allergic encephalomyelitis (EAE). DAC treatment was associated with a significant amelioration of the clinical and histological hallmarks of EAE in both models. These effects were observed both in prophylactic and therapeutic regimens. The milder course of the disease was associated with a reduction in the number of spinal cord infiltrating lymphocytes and amelioration of the histopathological signs associated with EAE. In addition, increased transcript levels of anti-inflammatory cytokines and decreased mRNA expression of pro-inflammatory mediators were also observed. Finally, DAC treatment increased the percentage of circulating regulatory T cells by inducing Foxp3 expression via demethylation of a CpG island in Foxp3.

UR - http://www.scopus.com/inward/record.url?scp=84906690218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906690218&partnerID=8YFLogxK

U2 - 10.1002/jcp.24641

DO - 10.1002/jcp.24641

M3 - Article

VL - 229

SP - 1918

EP - 1925

JO - Journal of cellular and comparative physiology

JF - Journal of cellular and comparative physiology

SN - 0021-9541

IS - 12

ER -